熱門資訊> 正文

Vaxcyte定价13亿美元股权发行

2024-09-05 14:37

Vaxcyte(PCVX) 0
輝瑞(PFE) 0

Clinical-stage vaccine innovation company Vaxcyte (NASDAQ:PCVX) priced of an underwritten public offering of ~10.19M shares and pre-funded warrants to purchase ~2.43M shares.
The shares of common stock are being sold at a public offering price of $103.00 per share.
Gross proceeds are expected to be ~$1.3B.
The offering is expected to close on September 6, 2024.

More on Vaxcyte

Biggest stock movers today: U, BA, X, and more
Vaxcyte pneumococcal shot matches Pfizer’s in early trial for safety
Seeking Alpha’s Quant Rating on Vaxcyte
Historical earnings data for Vaxcyte
Financial information for Vaxcyte

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。